Evidence map›Paper›PMID 37896895›Full record

ArticleViruses2023

Evaluation of Prevalence of Hepatitis E Clinical Markers among Donors in Estonia.

Tatiana Kuznetsova, Diana Moor, Gulara Khanirzayeva, Julia Geller

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Tatiana KuznetsovaDepartment of Infectious Disease Research, National Institute for Health Development, 11619 Tallinn, Estonia.ORCID 0000-0002-7285-5038
Diana MoorNorth Estonia Medical Centre's Blood Center, North Estonia Medical Centre Foundation, 13419 Tallinn, Estonia.
Gulara KhanirzayevaNorth Estonia Medical Centre's Blood Center, North Estonia Medical Centre Foundation, 13419 Tallinn, Estonia.ORCID 0009-0008-0037-5247
Julia GellerDepartment of Infectious Disease Research, National Institute for Health Development, 11619 Tallinn, Estonia.ORCID 0000-0001-6496-9687
National Institute for Health Development · EENorth Estonia Medical Centre · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis E virus (HEV) is now considered the most common cause of acute hepatitis worldwide. There are no published data about the prevalence of antibodies to HEV and RNA in donor sera in Estonia, and this precludes planning measures for preventing HEV proliferation through blood transfusion services. Here, were report data from an analysis of 1002 sera on the prevalence of anti-HEV IgG and IgM and the viral RNA. The antibodies were found in 48 donor sera (4.8%); of these, 40 (4%) harbored anti-HEV IgG, 15 (1.5%) contained anti-HEV IgM, and 7 donors had anti-HEV antibodies of both classes simultaneously. HEV RNA was not detected in any blood serum. Statistical associations of infection risk factors (gender, age, travel in the last six months, contact with pigs and/or wild boars in the last six months, consumption of thermally unprocessed/raw pork or boar meat, raw/unfiltered tap water or water from natural sources, unpasteurized farm dairy products, and unwashed berries and/or vegetables) were assessed. None of the listed factors were found to be associated with a higher or lower risk of anti-HEV antibody presence. At the same time, an increasing share of anti-HEV IgG carriers with age was found. The absence of HEV RNA in the analyzed donor plasma samples proves that HEV acute infection prevalence in Estonia does not exceed the average level of European countries. There is no urgent necessity to enter a requirement for a total screening of blood plasma for HEV RNA prevalence in Estonia.

Indexed as

Hepatitis EHepatitis E virusAnimalsBlood DonorsEstoniaHepatitis AntibodiesHumansImmunoglobulin GImmunoglobulin MPrevalenceRNA, ViralSeroepidemiologic StudiesSwineWaterHepatitis AntibodiesImmunoglobulin GImmunoglobulin MRNA, ViralWaterblood donorhepatitis E virusseroprevalence

Identifiers

PMID37896895
PMCPMC10612021
OpenAlexW4387779621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.